

INFORMATION RELEASE: - 3 APRIL 2009, BRISBANE

CBio is pleased to provide the following update:

CLINICAL TRIAL PROGRESS


The Company's Rheumatoid Arthritis clinical trial now has 15 active sites across Australia and New Zealand, with 56 patients successfully recruited into the study. 33 patients have passed the week 12 primary efficacy endpoint as determined by the protocol, whilst 16 patients have reached week 24 and therefore completed the study.

Whilst the trial remains blinded, the emerging trend is an extremely positive indicator for the success of the study, and the Company remains confident in the potential of its XToll® technology.


As a result of impaired manufacturing capacity which directly affects drug supply for the clinical trial, CBio has been forced to temporarily suspend recruitment into the trial. These manufacturing production issues will not impact patients currently in the trial and benefiting from treatment with XToll®.

RIGHTS ISSUE AND FUNDING

The recent Rights Issue has now concluded and (including Shortfall) raised \$1.494m. The Company continues to seek out and pursue all opportunities for the development and commercialisation of its XToll® technology.



Stephen Jones
Executive Chairman



Jason Yeates
Managing Director & CEO